NCT03596372 - Study of BAY1834942 in Patients With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 19, 2018

Primary Completion Date

November 16, 2020

Study Completion Date

February 22, 2021

Conditions

Advanced CEACAM6-expressing Solid Tumors

Interventions

DRUG

BAY1834942

"Dose escalation:~Sequential dose levels~.~Dose expansion (except for low-dose expansion):~With maximum tolerated dose (MTD) identified in dose escalation part."

Trial Locations (4)

37203

Sarah Cannon Research Institute, Nashville

77030

University of Texas MD Anderson Cancer Center, Houston

119074

National University Hospital, Singapore

M5G 2M9

Princess Margaret Hospital-University Health Network, Toronto